thats a joke, dumb people selling at market
Sentiment: Strong Buy
As soon as volume picks up she will bounce back.
Biotech investing is all about clinical data and overhyped promises. There are no news and/or any developments as of now. So, there is only computer trading takes place.
ARQL is a biotech with a mediocre and greedy bureaucrat as a CEO. The next stop is the ESMO conference with Marquee NSCLC OS results in late Sep unless something leaks out early.